Account
FCB Ulka to handle Hamdard creatives
MUMBAI: Hamdard Laboratories has assigned the creative mandate for its flagship brands to FCB Ulka following a multi-agency pitch.
Hamdard Laboratories, the 110-year old maker of iconic brands such as RoohAfza, Safi, Roghan Badam Shirin, Joshina, Sualin and a variety of Unani medicines, is in a transformational mode. New product launches and extensions, innovative brand communication and digital forays are now the norms at Hamdard, with a clear objective of building bridges with the young consumers and millennials.
As part of this mandate, FCB Ulka has been entrusted with the creative duties for Hamdard’s market-leading brands – RoohAfza, the recently launched ready to drink RoohAfza Fusion, SAFI, Joshina and Sualin. FCB Ulka’s Gurgaon office will lead this relationship.
Hamdard Laboratories chief sales and marketing officer Mansoor Ali says, “The creative mandate for such heritage brands is a huge responsibility, and we are happy to partner with FCB Ulka who came out with some path-breaking ideas in our meetings. Building bridges for heritage brands are not easy and we see the alignment of thought and purpose in FCB Ulka as a strategic partner. The future is heady and full of action, with new product launches and the need for innovative, even disruptive consumer advertising. I welcome the FCB team aboard.”
FCB India group chairman and CEO Rohit Ohri adds, “It is not often that advertising agencies get the opportunity to work on heritage brands like RoohAfza, Safi, Joshina & Sualin. We look forward to partnering Hamdard in this next exciting phase of growth in India and abroad. Our mission is to create ‘Never Finished’ ideas for these wonderful brands. Over the years, FCB Ulka has built and nurtured many heritage brands. We now proudly add Hamdard to that list.”
MUMBAI: BigTrunk Communications, an integrated digital marketing agency known for driving brand transformations across industries, has been awarded the digital marketing mandate for Soframycin, one of India’s most trusted antiseptic cream brands from the EncubeEthicals portfolio. With this collaboration, Soframycin makes its debut into the digital space, aiming to amplify its presence across India through compelling social media narratives and data-led campaigns. BigTrunk will lead the brand’s digital strategy and execution, with a focus on connecting Soframycin’s legacy of trust with today’s health-conscious and digitally engaged audience.
Soframycin has been a household name for generations, widely recognized for its efficacy in treating cuts, burns, and wounds. Backed by the scientific rigor and pharmaceutical expertise of EncubeEthicals, a pharmaceutical powerhouse since 1998, the brand benefits from the expertise of over 1,400 professionals, including more than 200 R&D specialists and a robust team of quality experts. With a presence in over 50 countries, Encube’s commitment to excellence in topical formulations adds deep credibility to Soframycin’s legacy. Now, as the brand enters the digital space, BigTrunk Communications will lead the charge in reimagining Soframycin’s story—creating modern, relatable digital experiences that stay true to its heritage.
“As we take Soframycin into its next chapter of growth, embracing digital media is not just a strategy but a necessity. We wanted a partner who could translate our scientific credibility into engaging, relatable content for today’s audience,” said Soframycin vice president – marketing, Ajay Rawal. “BigTrunk’s deep understanding of healthcare communications and digital behavior makes them the ideal partner to build meaningful narratives around wound care, trust, and wellbeing.”
“Soframycin is more than a product—it’s a legacy deeply rooted in care and science,” added BigTrunk Communications founder & managing director Bharat Subramaniam. “We’re excited to take on this responsibility of guiding a heritage brand into the digital world. Our focus will be on creating contextual storytelling and purpose-driven campaigns that bring Soframycin closer to Indian families, both old and new.”
